What is iatrogenic

Iatrogenic is a medical term commonly applied to illness, disorders, diseases or symptoms directly attributable to medical or surgical procedures or comments of a physician ¹. The harm that a physician can do is not limited to the imprudent use of medicine or procedure, but may include unjustified remarks and misinterpretation of investigational data.

Iatrogenic causes

Here are some examples of iatrogenic causes.

Adverse effects of diagnostic procedures

Mechanical procedures

Diagnostic aspiration of fluids may lead to hemorrhage, secondary infection, etc. Rapid pleural or peritoneal fluid aspiration and needle biopsies may lead to shock and even death. Endoscopic procedure may cause perforation of hollow viscus.

Diagnostic radiology

Reactions to contrast media injected intravenously or intra-arterially may be mild, moderate or severe, and some are potentially fatal. Intravascular contrast media may have a nephrotoxic reaction. Cerebral angiography may cause transient or permanent neurological deficits. Radioisotopes are safe except in pregnant mothers or in newborn ².

Adverse effects of therapeutic regimen

Adverse drug reactions

Adverse drug reactions is defined by World Health Organization as any response for a drug which is noxious, unintended and which occurs at doses normally used for prophylaxis, diagnosis and therapy of disease ³. Adverse drug reactions can be classified as predictable (side effects, toxicity, super infection, drug interactions) and unpredictable (intolerance, idiosyncrasy, allergy or pseudo allergy) ⁴.

When fewer than 6 different drugs are given in hospitalized patients, the probability of an adverse reaction is about 5%, but if more than 15 drugs are given, the probability is more than 20%. Of the patients admitted to a General hospital, 2 to 5% are due to adverse drug reactions and fatality in patients with adverse drug reactions varies from 2-12%. Adverse drug reactions occurs in the elderly more frequently ⁵.

To overcome the inadequacies in the WHO (World Health Organization) definition, new definition for adverse drug reaction is “an appreciably harmful or unpleasant reaction, resulting from an interaction related to the use of a medicinal product, which predicts hazard from future administration and warrants prevention or specific treatment or alteration of the dosage regimen or withdrawal of the product”. They are classified into six types (with mneminics), dose-related (Augmented), non-dose-related (Bizarre), dose-related and time-related (Chronic), time-related (Delayed), withdrawal (End of use), and failure of therapy (Failure) ⁶.

Anaphylaxis

Penicillin and other beta-lactum antibiotics and various types of vaccines and sera, and human insulin, are the most common agents that cause anaphylaxis. Aspirin and other nonsteroidal anti-inflammatory agents (NSAIDs) cause non-IgE mediated anaphylactoid reactions ⁷.

Drug induced cutaneous manifestations

Some of the cutaneous manifestations are ⁸:

1. Alopaecia: Cytotoxic agents
2. Erythema multiforme: Chlorpropamide, Sulphonamides
3. Exanthematous eruptions: Allopurinol, Anti convulsants
4. Exfoliative dermatitis: Gold, streptomycin
5. Fixed drug eruptions: Barbiturates, Tetracyclines
6. Photosensitivity: Griseofulvin, Indomethacin
7. Toxic epidermal necrolysis: Barbiturates, Sulphonamides

Drug induced hematological disorders

Megaloblastic anemia

Oral contraceptives, phenytoin, phenobarbitone and primidone cause megaloblastic anemia due to folic acid deficiency, colchicines, neomycin, paramino salicylic acid due to vitamin B12 deficiency and 6-mercaptopurine, 5 fluro-uracil, hydroxy-urea, acyclovir and zidovudine by interfering with DNA metabolism ⁹.
Hemolytic anemia

Drugs causing haemolysis by direct action are phenacetin, paramino salicylic acid, sulphonamides: by immune mechanism are aminopyrine, chlorpromazine, quinine and tetracycline: and in G6PD deficient patients, antimalarials (primaquine) and antibiotics (nitrofurantoin) ¹⁰.

Aplastic anemia

Drugs that regularly produce bone marrow depression: busulphan, cyclophosphamide, chlorambucil, vinblastine, and 6 mercaptopurine. Drugs which rarely produce bone marrow depression: chloramphenicol, penicillamine, sulphonamides, isoniazid, NSAIDSs, analgin, thiouracil, anticonvulsants, anti diabetics, cimetidine, tranquilizers etc ¹¹.

Drugs producing Neutropenia ¹²

• Analgesics and NSAIDs: Indomethcin, Phenacetin, Acetaminophen, Phenyl-Butazone and Aminopyrine
• Anticonvulsants: Phenytoin, Carbamazepine
• Antithyroid drugs: Thiouracil, Methimazole
• Phenothiazines: Chlorpromazine
• Antiarrhythmic: Quinidine

Drugs that cause thrombocytopaenia ¹²

Alpha-methyldopa, carbimazole, chloramphenicol, cyclosporins, phenylbutazone, quinine, quinidine, rifampicin, sulphonamides etc.

Hazards of blood transfusion

Complications occur in 2 percent of blood transfusions ¹³.

1. Immunological reaction: Allergic-anaphylaxis, fever, haemolysis, non cardiac pulmonary oedema.
2. Non immunological: Circulatory overload, thrombophlebitis and embolism, bacterial contamination, transmission of diseases like malaria, hepatitis, syphilis and AIDS and transfusion siderosis in multiple transfusion.

Drug induced gastro-intestinal diseases

Oral lesions ¹⁴

1. Lichen planus like lesions: methyldopa, chloroquine and propranolol.
2. Lupus erythematosis like lesions: hydralazine, gold. Acid peptic disease : acetyl salicylic acid, NSAIDs, corticosteroids etc.

Pancreatitis: azathioprine, glucocorticoids and oral contraceptives.

Malabsorption: broad-spectrum antibiotics, cholestyramine and neomycin.

Hepatic damage

Drug induced liver injury is a potential complication of nearly every medication because liver metabolizes virtually all drugs. Acute (acetaminophen, halothane) and chronic (nitrofurantoin, methyldopa) hepatocellular injury, veno occlusive disease (cyclophosphamide) and hepatocellular carcinoma (sex and anabolic hormones) can all occur. There are many new drugs like glyburide, ketoconazole, lisinopril, lovastatin, ticlopidine etc. which were also associated with hepatotoxic reactions. Among causes of fulminant hepatic failure certain drugs like halothane, acetaminophen, phenytoin and alpha methyldopa account for 20-50% of cases ¹⁵.

Respiratory disorders due to drugs

Type of reaction Example of drug ¹⁴

1. Airway obstruction (Bronchospasm): Beta-Blockers, Adenosine, NSAIDs
2. Cough: ACE inhibitors
3. Nasal congestion: Oral contraceptives, Reserpine, Guanithidine
4. Pulmonary oedema: Contrast media, Methadone, Interleukin 2
5. Pulmonary hypertension: Fenfluramine
6. Pulmonary infiltration: Anticancer agents, Acyclovir, Amiodarone
7. Pleural disease: Hydralazine, Methysergide
8. Pulmonary thromboembolism: Oral contraceptives

Drug induced cardiovascular diseases

Drug reactions may lead to exacerbation of angina (alpha blockers), arrhythmias (digitals, beta-adrenergic agents, tricyclic anti-depressants and quinine), cardiomyopathy (daunorubicin, emetine and lithium), hypo or hypertension (glucocorticoids and sympathomimetics), pericardial disease (emetine, procainamide and minoxidil), and Torsades de pointes (sparfloxacin) ¹⁴.

Renal disorders caused by drugs

The kidney is the main excretory organ of the body and hence affected by most drugs ¹⁶.

1. Directly toxic to the tubular cells: paracetamol, amphotericin B, cisplatin, sulphonamides etc.
2. Function as an antigen or as a hapten and the resulting antigen antibody reaction damages renal interstitium and leads to acute interstitial nephritis : penicillins, cephalosporins, NSAIDs, anticoagulants, gold salts, captopril etc.
3. Renal failure by reducing renal blood flow: noradrenaline and dopamine in high doses. NSAIDs indirectly affect renal blood flow by inhibiting production of prostaglandins.

Analgesic nephropathy – heavy and prolonged consumption of compound analgesic preparations particularly those containing phenacetin can cause chronic renal failure. This analgesic nephropathy is part of a broader analgesic syndrome, which includes hypertension, peptic ulcer, anaemia and recurrent headache.

Syndrome of drug-induced kidney disease

Common risk factors which precipitate adverse effects include old age, volume-depleted state, pre-existing renal dysfunction and co-existing use of other nephrotoxins.

Syndrome of drug-induced kidney disease

1. Pre-renal failure/functional renal failure: NSAIDs, ACE-inhibitors, Diuretics, Interleukin-2, Amphotericin-B.
2. Acute tubular necrosis: Aminoglycosides, Rifampicin, NSAIDs, Cyclosporine, Cisplatin
3. Acute Interstitial nephritis: Penicillins, NSAIDs, Allopurinol, Thiazides, Sulfonamides.
4. Thrombotic microangiopathy/hemolytic uremic syndrome: Mitomycin-C, Cyclosporine, Quinine, Cocaine, Clopidogrel.
5. Isolated proteinuria with nephritic syndrome: Gold, heroin, Captopril, NSAIDs, IFN-alpha, D-penicillamine.
6. Chronic tubulointerstitial disease: NSAIDs, Thiazides, Lithium, Chinese herb nephropathy, Germanium.
7. Retroperitoneal fibrosis: Methysergide, Hydralazine, Methyldopa.

Neurological manifestations

Neurological manifestations ¹⁷

1. Aseptic meningitis: Intravenous immunoglobulin
2. Extra pyramidal lesions: Haloperidol, Methyl dopa, Phenothiazine
3. Peripheral neuropathy: Isoniazid, Metronidazole, Gold salts, Nitrofurantoin, Amiodarone, Vaccines.
4. Pseudomotor Cerebri or intracranial hypertension: Amiodarone, Glucocorticoids, Oral contraceptives
5. Convulsions: Amphetamine, Analeptics, Lithium, Phenothiazine
6. Stroke: Oral contraceptives
7. Encephalitis and Guillain-Barre syndrome: Anti-rabies vaccination (purified chick embryo cell)
8. Myopathy: Statins

Neuroleptic malignant syndrome – Rigidity, hyperthermia, altered mental status resembling catatonia, labile blood pressure and autonomic dysfunction characterize one of the serious complications of neuroleptic agents like Haloperidol ¹⁸.

Drug induced psychiatric syndromes

Drug induced psychiatric syndromes ⁵

1. Delirium or Confusional state: Anticholinergics, Glucocorticoids, Phenothiazines
2. Depression: Beta blockers, Glucocorticoids, Nifedipine
3. Drowsiness: Antihistamines
4. Hallucination: Beta blockers, Levodopa, Narcotics
5. Hypomania, Mania: Glucocorticoids, Sympathomimetics
6. Paranoid states: Amphetamines

Drug induced musculoskeletal/rheumatic disorders

Drug induced musculoskeletal/rheumatic disorders ¹⁹

1. Arthralgia: Fluorides, growth hormone, Penicillin, Quinolones (in children), Sulphonamides
2. Hyper-uricaemia and Gout: Cytotoxic drugs, Cyclosporine, Salicylates Ethambutol, Levodopa, Nicotinic acid, Phenytoin, Diuretics.
3. Mylagia/Myositis: Amphotericin B, Chloroquine, Cimetidine, Clofibrate, Colchicines, Cyclosporines, Gemfibrozil, Lovastatin, Levodopa, Penicillamine, Phenytoin, Rifampicin, Vincristine, Zidovudine.
4. Osteoporosis: Anticonvulsants, Corticosteroids, Heparin, Methotrexate.
5. Scleroderma like disorder: Bleomycin, INH, Penicillamine, Silicon Breast implants.

Adverse reactions due to sudden stoppage of drug

Sudden stoppage of drugs can cause ²⁰:

1. “Rebound phenomenon” : relapse with or without exacerbation of the basic disease
2. “Withdrawal phenomenon” : a new clinical syndrome unrelated to the original disease

Antihypertensive drugs: Sudden stoppage of clonidine and alpha methyldopa cause syndrome resembling pheochromocytoma.

Beta-blockers: Sudden stopping of the drug in coronary artery disease may cause infarction, aggravation of angina or rhythm disorders.

Corticosteroids: Withdrawal accidents are seen after prolonged treatment, unrelated to the dose and duration of treatment and relapse of basic disease even in an aggravated form.

Barbiturates: Sudden stoppage in epileptic patients can induce status epilepticus. When used to induce sleep, sudden stoppage can cause acute insomnia, confusion, agitation, hallucinations and convulsions.

Drugs producing malignant diseases

Drugs producing malignant diseases ²¹

1. Leukemia (esp. acute myeloid leukemia) − Anti cancer agent, Radiotherapy, rarely Chloramphenicol and Phenyl-butazone
2. Cancer of breast and endometrium − Estrogens, Tamoxifen
3. Cancer of vagina − Diethyl stilbesterol
4. Liver cancer − Anabolic steroids, Oral contraceptives

Drug nutrient interaction

Drugs may decrease nutrient absorption, increase urinary excretion, directly compete with or antagonize the nutrient from a carrier protein and interfere with the synthesis of an enzyme or coenzyme essential for the metabolism of the nutrient ²².

Drug induced fever

Drug fever constitutes one percent of all fevers of unknown origin. Any drug can cause fever (antihistamines, barbiturates, iodides, penicillins, phenytoin, propylthiouracil, β-lactum antibiotics etc). A history of allergy, skin rash or eosinophilia is often absent in cases of drug fever ²³.

Adverse reactions following immunization

Adverse reactions following immunization ²⁴

1. Inherent vaccine induced
   • (a) Mild and common – local reaction, fever
   • (b) Moderately severe and uncommon – suppurative lymphadenitis (BCG vaccination)
   • (c) Severe and rare-Encephalopathy and hypersensitive reactions (paralytic polio following oral polio vaccine).
2. Programmatic errors: Septic – toxic shock syndrome and abscess.

Interaction between indigenous and prescription drugs

Use of indigenous drugs is neither inquired in the drug history nor are the patients advised to avoid such an indiscriminate concurrent use of drugs. Sometimes these factors lead to either a therapeutic failure or a drug interaction or an accentuation of the unknown toxicities of the chemical prescription drugs ²⁵.

Ophthalmological complications

Ophthalmological complications ⁵

1. Cataract: Busulphan
2. Corneal opacities: Chloroquine
3. Colour vision alteration: Digitalis
4. Glaucoma: Sympathomimetics
5. Optic neuritis: Quinine
6. Retinopathy: Chloroquine

Radiation hazards

Radiation hazards ⁵

1. Acute and chronic progressive radiation injuries
2. Pneumonitis
3. Glomerulosclerosis and chronic interstitial nephropathy
4. Enteritis and cystitis
5. Venoocclusive disease of liver
6. Bone marrow depression
7. Malignancy

Hazards of hospitalization

The prevalence of hospital-acquired infections is around 10%. Urinary tract infections and respiratory infections are the commonest. There is increased chance of infections associated with diagnostic and therapeutic procedures and with antibiotic resistant bacterial flora ²⁶.

Iatrogenic Cushing syndrome

Iatrogenic Cushing syndrome is Cushing syndrome due to your body being exposed to corticosteroid drugs or exogenous glucocorticoid products for a long time. Corticosteroid drugs contain a man-made version of cortisol. One example is taking oral corticosteroid medications in high doses over an extended period of time. Drugs that have been reported to result in iatrogenic Cushing syndrome are glucocorticoids, megestrol acetate, and herbal preparations that contain glucocorticoids. These medications, such as prednisone, have the same effect in the body as does cortisol produced by your body.

Oral corticosteroids may be necessary to treat inflammatory diseases, such as rheumatoid arthritis, lupus and asthma, or to prevent your body from rejecting a transplanted organ. Because the doses required to treat these conditions are often higher than the amount of cortisol your body normally needs each day, side effects from excess cortisol can occur.

It’s also possible to develop Cushing syndrome from injectable corticosteroids — for example, repeated injections for joint pain, bursitis and back pain. Inhaled steroid medicines (taken for asthma) and steroid skin creams (used for skin disorders such as eczema) are generally less likely to cause Cushing syndrome than oral corticosteroids. But, in some individuals, these medications may cause Cushing syndrome, especially if taken in high doses.

Too much cortisol can produce some of the hallmark signs of Cushing syndrome — a buffalo hump between your shoulders, a rounded face, and pink or purple stretch marks on your skin. Cushing syndrome can also result in high blood pressure, bone loss and, on occasion, type 2 diabetes.

Morbidity and mortality associated with iatrogenic Cushing syndrome are related primarily to the effects of excess glucocorticoids.

Two catastrophic medical crises that occur in glucocorticoid excess states are perforated viscera and opportunistic fungal infections. Exposure to excess glucocorticoids results in multiple medical problems, including hypertension, obesity, osteoporosis, fractures, impaired immune function, impaired wound healing, glucose intolerance, and psychosis.

Exogenous steroids suppress the hypothalamic pituitary axis, with full recovery taking as long as a year after cessation of glucocorticoid administration. Thus, patients who are on or who have taken steroids are at risk for developing an adrenal crisis if steroids are stopped or not increased during an acute illness.

Glucocorticoids’ bioavailability is between 60% and 100%. More than 90% of the circulating glucocorticoid binds to corticosteroid binding globulin. The unbound free hormone in the circulation binds to the glucocorticoid receptor (GR). Glucocorticoid receptor consists of a carboxy terminal ligand binding domain, a DNA binding domain and an N terminal domain. Except for prednisolone, which has an affinity for corticosteroid binding globulin that is about half of cortisol. Other synthetic glucocorticoids, in comparison to cortisol, have much less affinity to corticosteroid binding globulin.

Binding of the glucocorticoid to glucocorticoid receptorresults in several intracellular processes of gene transcription and translation that ultimately lead to several actions of glucocorticoids on tissues. Some glucocorticoids can have cross activity with mineralocorticoid receptor (MR) due to significant homology between glucocorticoid receptor and mineralocorticoid receptor ²⁷.

Structural differences between glucocorticoid compounds result in different bioavailability, duration, onset of action, potency and metabolic profiles of each product. Downregulation of the nuclear factor-kappa B activation ²⁸, changes in the enzyme adenosine monophosphate-activated protein kinase activity ²⁹ and modulation of activator protein 1 (Fos/Jun) ³⁰ are some of the important pathways that have been described. More research still needs to be conducted to fully understand the underlying signaling pathways and glucocorticoid tissue-specific responses.

A study by Serfling et al suggested that weight gain in iatrogenic Cushing syndrome may be related to a glucocorticoid-stimulated rise in the amygdala and insula’s blood oxygen level–dependent (BOLD) response to approach-associated food stimuli. Thus, glucocorticoids may increase the anticipated reward value of food, leading to greater food consumption ³¹.

Iatrogenic Cushing syndrome symptoms

Symptoms of Cushing’s syndrome can start suddenly or gradually. They tend to get slowly worse if not treated.

Common signs and symptoms of Cushing’s syndrome involve progressive obesity and skin changes, such as:

• Weight gain and fatty tissue deposits, particularly around the midsection and upper back, in the face (moon face), and between the shoulders (buffalo hump), increased fat on your chest and tummy, but slim arms and legs
• Pink or purple stretch marks (striae) on the skin of the abdomen, thighs, breasts and arms
• Thinning, fragile skin that bruises easily
• Slow healing of cuts, insect bites and infections
• A red, puffy, rounded face
• Acne

Cushing’s syndrome can also cause high blood pressure, which can be serious if not treated.

Women with Cushing syndrome may experience:

• Thicker or more visible body and facial hair (hirsutism)
• Irregular or absent menstrual periods

Men with Cushing syndrome may experience:

• Decreased libido
• Decreased fertility
• Erectile dysfunction

Other signs and symptoms include:

• Severe fatigue
• Muscle weakness
• Depression, anxiety and irritability
• Loss of emotional control
• Cognitive difficulties
• New or worsened high blood pressure
• Headache
• Bone loss, leading to fractures over time
• In children, impaired growth

Iatrogenic Cushing syndrome complications

Without treatment, complications of Cushing syndrome may include:

• Bone loss (osteoporosis), which can result in unusual bone fractures, such as rib fractures and fractures of the bones in the feet
• High blood pressure (hypertension)
• Type 2 diabetes
• Frequent or unusual infections
• Loss of muscle mass and strength

Iatrogenic Cushing syndrome diagnosis

If you’ve been taking a corticosteroid medication for a long time, your doctor may suspect that you’ve developed Cushing syndrome as a result of this medication. If you haven’t been using a corticosteroid medication, these diagnostic tests may help pinpoint the cause:

• Urine and blood tests. These tests measure hormone levels in your urine and blood and show whether your body is producing excessive cortisol. For the urine test, you may be asked to collect your urine over a 24-hour period. Both the urine and blood samples will be sent to a laboratory to be analyzed for cortisol levels. Your doctor might also recommend other specialized tests that evaluate the blood and urine to help determine if Cushing syndrome is present and to help identify the underlying source of any excess production. These tests often involve measuring cortisol levels before and after stimulation or suppression with other hormone medications.
• Saliva test. Cortisol levels normally rise and fall throughout the day. In people without Cushing syndrome, levels of cortisol drop significantly in the evening. By analyzing cortisol levels from a small sample of saliva collected late at night, doctors can see if cortisol levels are too high, suggesting a diagnosis of Cushing syndrome.
• Imaging tests. Computerized tomography scans or magnetic resonance imaging scans can provide images of your pituitary and adrenal glands to detect abnormalities, such as tumors.
• Petrosal sinus sampling. This test can help determine whether the cause of endogenous Cushing syndrome is rooted in the pituitary or somewhere else. For the test, blood samples are taken from the petrosal sinuses — veins that drain the pituitary glands. A thin tube is inserted into your upper thigh or groin area while you’re sedated, and threaded to the petrosal sinuses. Levels of ACTH are measured from the petrosal sinuses, and from a blood sample taken from the forearm. If ACTH is higher in the sinus sample, the problem stems from the pituitary. If the ACTH levels are similar between the sinus and forearm, the root of the problem lies outside of the pituitary gland.

These tests don’t only help your doctor diagnose Cushing syndrome, they may also help rule out other medical conditions with similar signs and symptoms. For example, polycystic ovary syndrome — a hormone disorder in women with enlarged ovaries — shares some of the same signs and symptoms as Cushing has, such as excessive hair growth and irregular menstrual periods. Depression, eating disorders and alcoholism also can partially mimic Cushing syndrome.

Iatrogenic Cushing syndrome treatment

Treatments for Cushing syndrome are designed to lower the high level of cortisol in your body. The best treatment for you depends on the cause of the syndrome.

Reducing corticosteroid use. If the cause of Cushing syndrome is long-term use of corticosteroid medications, your doctor may be able to keep your Cushing signs and symptoms under control by reducing the dosage of the drug over a period of time, while still adequately managing your asthma, arthritis or other condition. For many of these medical problems, your doctor can prescribe noncorticosteroid drugs, which will allow him or her to reduce the dosage or eliminate the use of corticosteroids altogether. Don’t reduce the dose of corticosteroid drugs or stop taking them on your own. Do so only under your doctor’s supervision. Abruptly discontinuing these medications could lead to deficient cortisol levels. Slowly tapering off corticosteroid drugs allows your body to resume normal cortisol production.

Iatrogenic pneumothorax

A pneumothorax, also known as a collapsed lung, occurs when air (either from the lung or outside) collects in the space between the lung and the chest wall. Pneumothorax can present in one of three ways: spontaneous (primary), secondary, and traumatic. An iatrogenic pneumothorax is a known complication of invasive procedures such as pulmonary needle biopsy (transthoracic and transbronchial), placement of a central venous line, or positive pressure ventilation ³². However, this condition can arise from many other procedures involving the thorax and abdomen. Case reports include bilateral pneumothoraces after incorrect placement of a nebulization kit in a spontaneously breathing intubated patient ³³. after insertion of a hypoglossal nerve stimulator ³⁴, or even after acupuncture ³⁵. Subclavian insertion of a central venous line, however, is the most common procedure associated with an iatrogenic pneumothorax ³⁶.

In landmark-based subclavian central venous catheter placement, per Kilbourne et al. ³⁷, six common technical errors include inadequate landmark identification, improper insertion position, insertion of the needle through periosteum, taking too shallow a trajectory with the needle, aiming the needle too cephalad, and failure to keep the needle in place for wire passage. Landmark technique also depends on the ability and experience of the medical professional performing the procedure, making iatrogenic pneumothorax more likely in a tertiary teaching hospital ³⁸.

Iatrogenic pneumothorax is often avoidable, and in many cases can be prevented through adherence to evidence-based guidelines and procedural techniques known to reduce the incidence of iatrogenic pneumothorax ³⁹. Ultrasound guidance during internal jugular central venous catheter insertion is associated with a lower risk as compared to guidance by anatomical landmarks ⁴⁰. Other bedside procedures that are known to cause iatrogenic pneumothorax include thoracentesis. This risk can also be reduced with the use of ultrasound guidance ⁴¹.

The incidence of an iatrogenic pneumothorax is directly proportional to the number of invasive procedures performed ⁴². Patients in unstable trauma or code situations are more likely to undergo an invasive intervention. This along with limited access to internal jugular sites when a non-femoral vein site is desired results in an elevated risk for iatrogenic pneumothorax ⁴³.

Iatrogenic pneumothorax signs and symptoms

The presentation in a patient with a pneumothorax can range from asymptomatic to life-threatening based on the size, rate of development, and the health of the underlying lung. An iatrogenic pneumothorax is part of a differential diagnosis in a patient with pleuritic pain and dyspnea, tachypnea, and tachycardia. Decreased or absent breath sounds on the affected side is highly suspicious. Any pneumothorax can become a tension pneumothorax. Findings could include hypoxia, hypotension, distended neck veins, a displaced trachea, and unilaterally decreased breath sounds ⁴⁴.

Iatrogenic pneumothorax complications

Tension pneumothorax is the most notable complication of any pneumothorax previously described. This disorder is life-threatening and requires immediate intervention ⁴⁵. Another well-described complication of pneumothorax is having a persistent air leak and/or failure of lung re-expansion, which usually require further surgical intervention ⁴⁶.

Iatrogenic pneumothorax diagnosis

Iatrogenic pneumothorax can be diagnosed clinically. Point-of-care ultrasound has the advantage of being rapid, highly sensitive and specific, and easily repeatable. Suggestive findings include the lack of pleural sliding. A “point sign” (sliding pleural next to non-sliding pleura) is diagnostic. An upright posteroanterior chest radiography has 83% sensitivity ⁴⁴. Chest CT is more sensitive than chest radiography but inherently results in a delay in treatment.

Iatrogenic pneumothorax treatment

First, determine if the patient is stable or unstable. Next, provide supplemental oxygen at a rate to maintain adequate oxygenation ⁴⁷. Some patients with small pneumothoraces may resolve with observation ⁴⁸. Definitive treatment options of a pneumothorax include needle aspiration, chest tube drainage, video-assisted thoracic surgery (VATS), and open surgical intervention ⁴⁹. Treatment takes precedence over imaging. If felt to be clinically unstable, the traditional first step is to perform a needle aspiration or decompression to reduce the excess air in the pleural space. Place a large-bore needle in the second intercostal space in the midclavicular line as a temporary measure ⁵⁰. Finger thoracostomy is the most recently used technique. One makes an incision over the lateral chest wall in the “safe triangle” formed by the lateral border of the pectoralis major, the lateral border of the latismus dorsi, the fifth intercostal space, and the base of the axilla. Next, one inserts a finger over the fifth intercostal space and bluntly dissects into the pleural space. It is fast and safe as it does not cause a pneumothorax and addresses the increasing girth of today’s patients. Thoracostomy is the definitive therapy and uses the negative pressure generated by a water seal or suction to reduce air in the pleural space ⁵¹. Chest tubes are inserted in either the second or third intercostal space of the midclavicular line (Monaldi position). They can also be inserted anterior to the mid-axillary line of the fourth or fifth intercostal space (Bulau position) ⁵². The other two treatment choices are purely surgical and reserved for severe cases ⁵³.

Iatrogenic pneumothorax prognosis

The estimated risk of pneumothorax recurrence is 23% to 50% over a 1- to 5-year follow-up period, with the highest risk during the first month ⁵⁴. However, there is no data for recurrence or incidence changes specific to iatrogenic pneumothoraces. In patients who underwent tube thoracostomy, it is safe for them to fly as early as 72 hours after tube removal without increased risk of recurrence ⁵⁵.

Iatrogenic infection

Healthcare-related infections are considered a failure of the system. As much as one in 20 hospitalized patients may acquire a healthcare-related infection which may increase complications, length, and cost of the hospital stay.

Causes of hospital-acquired infections include:

• Failure to practice basic hand hygiene.
• Poor technique in placing indwelling Foley and vascular catheters.

Iatrogenic infection organisms

Acinetobacter baumannii has mainly been found in the intensive care unit and in other areas of the hospital where critically ill patients are managed. The bacteria do not pose a threat to healthy individuals but can lead to a severe infection in patients with a suppressed immune system. These organisms have been found to cause meningitis and pneumonia, wound infections, and urinary tract infections. Another major concern is that Acinetobacter is rapidly developing resistance to many of the commonly used antibiotics.

Bacteroides fragilis is a normal occurring organism in the colon. The organism is generally not harmful but is an opportunist. When patients take antibiotics, this cansuppress other normal flora and allow Bacteroides to enter the systemic circulation. The slow growth of bacteria and its occurrence with other colon pathogens often makes treatment difficult.

Clostridium difficile is the most well-known because of its ability to induce life-threatening colitis. The bacteria thrive in the presence of antibiotics and can easily spread via the oral-fecal route in a hospital setting. Clostridium difficile is resistant to most routine cleaning solutions, including alcohol-based sanitizers. Clostridium difficile can be treated, but in some cases, a fecal transplant may be required.

Carbapenem-resistant Enterobacteriaceae have become very common in hospitalized patients. These organisms are easily transferred from human to human by contact with skin or an infected device such as a Foley catheter. High mortality rates occur in patients who develop sepsis with these resistant organisms.

Enterococcus faecalis is a highly resistant colonic organism. Most isolated cases in hospitals reveal that this strain is resistant to vancomycin, leaving very few treatment options for patients. While enterococcus is normally found in the colon, it can enter the systemic circulation and cause sepsis, wound infections, urinary tract infections, and even pneumonia.

Escherichia coli is another gram-negative organism found in the intestinal tract, but it can become pathogenic when the opportunity arises. It is the most common cause of urinary tract infections in hospitalized patients. The 0157.H7 strain can cause hemolytic uremic syndrome.

Klebsiella pneumoniae is a common cause of pneumonia, urinary tract infections, wound infections, and meningitis. The risk of infection with Klebsiella is greater in patients with catheters and those on ventilators. Many species of Klebsiella are resistant to traditional antibiotics. These organisms are often a cause of infections in the neonatal intensive care unit and carry a high morbidity and mortality.

Other organisms that are associated with hospitalized patients include methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus aureus, Stenotrophomonas maltophilia, and vancomycin-resistant Staphylococcus aureus.

Iatrogenic infection prevention

Appropriate hand-washing is one of the single most effective methods to decrease infection transfer. High-risk procedures such as indwelling Foley catheter and vascular catheter infection rates can be decreased by adhering to the use of sepsis bundles.

Effective hand washing is linked to decreased morbidity and mortality rates. Sink availability or alcohol-based hand rubs prevent nosocomial infections. The Centers for Disease Control and Prevention guidelines include:

• Avoiding artificial nails.
• Changing gloves after each patient is evaluated or treated.
• Keeping natural nails less than one-fourth of an inch long.
• Use alcohol-based hand rubs.
• Washing hands with soap and water.

Hospital-acquired pneumonia causes significant morbidity and mortality. Risk factors include anemia, malnutrition, chronic renal failure, depressed mental status, thoracic surgery, and recent hospitalization. While decreasing hospital-acquired infections is a difficulty, attention to risk factors and interventions may help decrease the incidence. Clostridium difficile-associated infection has become a significant problem. Clostridium difficile is most associated with the use of clindamycin, cephalosporin, and penicillin and warrants frequent surveillance.

References

1. Krishnan NR, Kasthuri AS. Iatrogenic Disorders. Med J Armed Forces India. 2011;61(1):2–6. doi:10.1016/S0377-1237(05)80107-8 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923397
2. Sutton D, Gregson R. Arteriography and interventional angiography. In: Sutton D, editor. Textbook of radiology and imaging. 6th ed. Churchill Livingstone; New York: 1998. p. 681
3. WHO . Tech Rep Ser. WHO; 1972. International drug monitoring: the role of national centers; p. 498
4. Kishore K, Nagarkar KM. Adverse drug reaction. Hospital today. 1996:35–41
5. Wood AJJ. Adverse Reactions to Drugs. In: Fauci SAS, Braunwald E, Kasper DL, Hauser SL, editors. Harrison’s Principles of Internal Medicine. 15th ed. McGraw Hill; New York: 2001. pp. 430–438
6. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis and management. The Lancet. 2002;356:1255–1259
7. Marquarit DL. Anaphylaxis and Drug Reactions. In: Stein JH, editor. Internal Medicine. 5th ed. Little Brown; Boston: 1998. p. 1193
8. Hood AF. Cutaneous Manifestations of Drug Reactions. In: Stein JH, editor. Internal Medicine. 5th ed. Little Brown; Boston: 1998. pp. 1312–1316. [Google Scholar]Hood AF. Cutaneous Manifestations of Drug Reactions. In: Stein JH, editor. Internal Medicine. 5th ed. Little Brown; Boston: 1998. p. 1402
9. Agarwal MB. Hereditary Hemolytic Anaemia. In: Shah SN, editor. API Text Book of Medicine. 7th ed. API; Mumbai: 2003. pp. 939–944
10. Nayak J. Megaloblastic Anaemia. In: Shah SN, editor. API Text Book of Medicine. 7th ed. API; Mumbai: 2003. pp. 934–938
11. Velu N. Bone Marrow Facture Status. In: Shah SN, editor. API Text book of Medicine. 7th ed. API; Mumbai: 2003. pp. 963–966
12. Bichile SK. Neutropenia (granulocytopenia, agranulocytosis) In: Shah SN, editor. API Text Book of Medicine. 7th ed. API; Mumbai: 2003. pp. 967–968
13. Kamath SA. Blood Transfusions. In: Shah SN, editor. API Text Book of Medicine. 7th ed. API; Mumbai: 2003. pp. 980–982
14. Wood AJJ. Adverse Reactions to Drugs. In: Fauci SAS, Braunwald E, Kasper DL, Hauser SL, editors. Harrison’s Principles of Internal Medicine. 15th ed. McGraw Hill; New York: 2001. pp. 430–438.
15. Sherlock S, Dooley J. Drugs and the Liver. In: Sherlock S, editor. Diseases of Live and Biliary System. 11th ed. Blackwell Scientific Publications; London: 2002. p. 335
16. Jacob CK. Drugs Toxins and the Kidney. In: Shah SN, editor. API Text Book of Medicine. 7th ed. API; Mumbai: 2003. pp. 668–672
17. Wadia RS, Dalal PM. Drug induced neuromuscular disorders. J Assoc Physicians India. 1994;42(7):537–539
18. Aminoff MJ. Parkinson’s disease and other Extra Pyramidal Disorders:-Neuroleptic Malignant Syndrome. In: Fauci SAS, Braunwald E, Kasper DL, Hauser SL, editors. Harrison’s Principles of Internal Medicine. 15th ed. McGraw Hill; New York: 2001. p. 2405
19. Joshi VR, Balakrishnan C. Drug induced Rheumatic Disorders. J Assoc Physicians India. 1994;42(1):805–808
20. Wahi S, Wahi PL. Adverse reactions on stoppage of drugs. J Assoc Physicians India. 1986;34:205–208
21. Advani SH. Basic consideration of oncology. In: Shah SN, editor. API Text Book of Medicine. 7th ed. API; Mumbai: 2003. pp. 987–990
22. Weser E, Young EA. Nutrition in Internal Medicine: Durg Nutrient Interaction. In: Stein JH, editor. Internal Medicine. 5th ed. Little Brown; Boston: 1998. pp. 2099–2112
23. Tauber MG. Fever of unknown Origin-Drug fever. In: Stein JH, editor. Internal Medicine. 5th ed. Little Brown; Boston: 1998. p. 1378
24. Adverse Events Following Immunization. CSSM Review. 1994:231–235
25. Rai J. A potential for interactions between indigenous and prescription drugs. In: Shah SN, editor. 7th ed. Vol. 52. API; Mumbai: 2003. pp. 164–166. API Text Book of Medicine
26. Mandal BK, Dunbar EM, Mayon White RJ. Hospital Acquired infection. In: Mandal, editor. Infectious Disease. 5th ed. Blackwell Science; Bangalore: 1996. p. 26
27. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Williams Textbook of Endocrinology. 12th ed. Elsevier Health Sciences; May 12, 2011. 488-491.
28. Meduri GU, Muthiah MP, Carratu P, Eltorky M, Chrousos GP. Nuclear factor-kappaB- and glucocorticoid receptor alpha- mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation. 2005. 12(6):321-38
29. Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G, et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing’s syndrome. FASEB J. 2008 Jun. 22(6):1672-83
30. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell. 1990 Sep 21. 62(6):1189-204
31. Serfling G, Buades-Rotger M, Harbeck B, Kramer UM, Brabant G. The corticosteroid prednisolone increases amygdala and insula reactivity to food approach signals in healthy young men. Psychoneuroendocrinology. 2018 Sep 8. 99:154-65
32. Loiselle A, Parish JM, Wilkens JA, Jaroszewski DE. Managing iatrogenic pneumothorax and chest tubes. J Hosp Med. 2013 Jul;8(7):402-8
33. Garg SK, Garg P, Anchan N, Jaiswal A. Iatrogenic Bilateral Simultaneous Pneumothorax: Call for Vigilance. Indian J Crit Care Med. 2017 Sep;21(9):607-609
34. Arteaga AA, Pitts KD, Lewis AF. Iatrogenic pneumothorax during hypoglossal nerve stimulator implantation. Am J Otolaryngol. 2018 Sep – Oct;39(5):636-638
35. Tagami R, Moriya T, Kinoshita K, Tanjoh K. Bilateral tension pneumothorax related to acupuncture. Acupunct Med. 2013 Jun;31(2):242-4
36. Shieh L, Go M, Gessner D, Chen JH, Hopkins J, Maggio P. Improving and sustaining a reduction in iatrogenic pneumothorax through a multifaceted quality-improvement approach. J Hosp Med. 2015 Sep;10(9):599-607
37. Kilbourne MJ, Bochicchio GV, Scalea T, Xiao Y. Avoiding common technical errors in subclavian central venous catheter placement. J. Am. Coll. Surg. 2009 Jan;208(1):104-9.
38. John J, Seifi A. Incidence of iatrogenic pneumothorax in the United States in teaching vs. non-teaching hospitals from 2000 to 2012. J Crit Care. 2016 Aug;34:66-8
39. Giacomini M, Iapichino G, Armani S, Cozzolino M, Brancaccio D, Gallieni M. How to avoid and manage a pneumothorax. J Vasc Access. 2006;7(1):7–14
40. McGee WT, Mailloux PT, Martin RT. Safe placement of central venous catheters: a measured approach. J Intens Care Med. 2011;26(6):392–396
41. Duncan DR, Morgenthaler TI, Ryu JH, Daniels CE. Reducing iatrogenic risk in thoracentesis: establishing best practice via experiential training in a zero-risk environment. Chest. 2009;135(5):1315–1320
42. Celik B, Sahin E, Nadir A, Kaptanoglu M. Iatrogenic pneumothorax: etiology, incidence and risk factors. Thorac Cardiovasc Surg. 2009 Aug;57(5):286-907
43. Shieh L, Go M, Gessner D, Chen JH, Hopkins J, Maggio P. Improving and sustaining a reduction in iatrogenic pneumothorax through a multifaceted quality-improvement approach. J Hosp Med. 2015 Sep;10(9):599-60
44. Swierzy M, Helmig M, Ismail M, Rückert J, Walles T, Neudecker J. [Pneumothorax]. Zentralbl Chir. 2014 Sep;139 Suppl 1:S69-86; quiz S87
45. Roberts DJ, Leigh-Smith S, Faris PD, Blackmore C, Ball CG, Robertson HL, Dixon E, James MT, Kirkpatrick AW, Kortbeek JB, Stelfox HT. Clinical Presentation of Patients With Tension Pneumothorax: A Systematic Review. Ann. Surg. 2015 Jun;261(6):1068-78
46. Slade M. Management of pneumothorax and prolonged air leak. Semin Respir Crit Care Med. 2014 Dec;35(6):706-14
47. Haynes D, Baumann MH. Management of pneumothorax. Semin Respir Crit Care Med. 2010 Dec;31(6):769-80
48. Hefny AF, Kunhivalappil FT, Matev N, Avila NA, Bashir MO, Abu-Zidan FM. Management of computed tomography-detected pneumothorax in patients with blunt trauma: experience from a community-based hospital. Singapore Med J. 2018 Mar;59(3):150-154
49. Tupchong K. Update: Is Needle Aspiration Better Than Chest Tube Placement for the Management of Primary Spontaneous Pneumothorax? Ann Emerg Med. 2018 Jul;72(1):e1-e2
50. Bruschettini M, Romantsik O, Ramenghi LA, Zappettini S, O’Donnell CP, Calevo MG. Needle aspiration versus intercostal tube drainage for pneumothorax in the newborn. Cochrane Database Syst Rev. 2016 Jan 11;(1):CD011724
51. Wang C, Lyu M, Zhou J, Liu Y, Ji Y. Chest tube drainage versus needle aspiration for primary spontaneous pneumothorax: which is better? J Thorac Dis. 2017 Oct;9(10):4027-4038
52. Drinhaus H, Annecke T, Hinkelbein J. [Chest decompression in emergency medicine and intensive care]. Anaesthesist. 2016 Oct;65(10):768-775
53. Delpy JP, Pagès PB, Mordant P, Falcoz PE, Thomas P, Le Pimpec-Barthes F, Dahan M, Bernard A., EPITHOR project (French Society of Thoracic and Cardiovascular Surgery). EPITHOR project French Society of Thoracic and Cardiovascular Surgery. Surgical management of spontaneous pneumothorax: are there any prognostic factors influencing postoperative complications? Eur J Cardiothorac Surg. 2016 Mar;49(3):862-7
54. Baumann MH, Strange C, Heffner JE, Light R, Kirby TJ, Klein J, Luketich JD, Panacek EA, Sahn SA., AACP Pneumothorax Consensus Group. Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. Chest. 2001 Feb;119(2):590-602
55. Zonies D, Elterman J, Burns C, Paul V, Oh J, Cannon J. Trauma patients are safe to fly 72 hours after tube thoracostomy removal. J Trauma Acute Care Surg. 2018 Sep;85(3):491-494